A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study.

ABSTRACT:

Background

Tumour necrosis factor receptor 1 (TNFR1) signalling mediates the cell death and inflammatory effects of TNF-α.

Objective

The current clinical trial investigated the effects of a nebulised TNFR1 antagonist (GSK2862277) on signs of lung injury in patients undergoing oesophagectomy.

Design

Randomised double-blind (sponsor unblind), placebo-controlled, parallel group study.

Setting

Eight secondary care centres, the United Kingdom between April 2015 and June 2017.

Patients

Thirty-three patients undergoing elective transthoracic oesophagectomy.

Interventions

Patients randomly received a single nebulised dose (26 mg) of GSK2862277 (n = 17) or placebo (n = 16), given 1 to 5 h before surgery; 14 and 16, respectively competed the study.

Main

SUBMITTER: Ryan J 

PROVIDER: S-EPMC7575021 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature